TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON-Reference-Cited by-同舟云学术

TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON

Published:2016-05 Issue:2 Volume:279 Page:630-640
ISSN:0033-8419
Container-title:Radiology
language:en
Short-container-title:Radiology

Author:

Geschwind Jean-François,Kudo Masatoshi,Marrero Jorge A.,Venook Alan P.,Chen Xiao-Ping,Bronowicki Jean-Pierre,Dagher Lucy,Furuse Junji,Ladrón de Guevara Laura,Papandreou Christos,Sanyal Arun J.,Takayama Tadatoshi,Ye Sheng-Long,Yoon Seung Kew,Nakajima Keiko,Lehr Robert,Heldner Stephanie,Lencioni Riccardo

Publisher

Radiological Society of North America (RSNA)

Subject

Radiology, Nuclear Medicine and imaging

Link

http://pubs.rsna.org/doi/pdf/10.1148/radiol.2015150667

Reference33 articles.

1. Hepatocellular carcinoma: clinical frontiers and perspectives

2. Risk Factors of Hepatocellular Carcinoma - Current Status and Perspectives

3. Hepatocellular carcinoma

4. Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects

5. Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version

Cited by 96 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transarterial Chemoembolization Treatment Paradigms for Hepatocellular Carcinoma;Cancers;2024-07-01

2. Treatment of Hepatocellular Carcinoma with Combined Transarterial Chemoembolization and Systemic Therapy;Seminars in Interventional Radiology;2024-06

3. Multidisciplinary Care and Multimodal Treatment Approaches for Unresectable Hepatocellular Carcinoma;Advances in Oncology;2024-05

4. The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE);Current Oncology;2024-03-13

5. Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study;Discover Oncology;2024-03-09